Simplify Asset Management Inc. Makes New $955,000 Investment in Vor Biopharma Inc. $VOR

Simplify Asset Management Inc. bought a new stake in Vor Biopharma Inc. (NASDAQ:VOR) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 53,510 shares of the company’s stock, valued at approximately $955,000. Simplify Asset Management Inc. owned about 0.11% of Vor Biopharma at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Cannon Global Investment Management LLC acquired a new stake in shares of Vor Biopharma during the 1st quarter worth approximately $209,000. XTX Topco Ltd acquired a new position in Vor Biopharma in the fourth quarter valued at approximately $229,000. Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma in the fourth quarter worth approximately $134,000. Tudor Investment Corp ET AL acquired a new stake in Vor Biopharma during the fourth quarter worth $2,193,000. Finally, Sphera Funds Management LTD. acquired a new stake in Vor Biopharma during the fourth quarter worth $5,368,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Insider Transactions at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 2,742,903 shares of company stock worth $44,672,376 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on VOR. Wells Fargo & Company began coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Wedbush boosted their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Stock Performance

VOR stock opened at $20.59 on Friday. The business’s fifty day moving average price is $15.15 and its 200 day moving average price is $14.66. Vor Biopharma Inc. has a 12-month low of $6.50 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, equities analysts anticipate that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).